%0 Journal Article
%B European Heart Journal
%D 2013
%G eng
%P 1279-91
%T HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
%V 34
%7 26 February 2013